Skip to content

OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) reimbursed for treatment of unresectable malignant mesothelioma

By Gold Cross - June 23, 2021

Microscopic view of Mesothelioma cancer cells infiltrating the beige fibrous lung pleura.
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

Unlocking the science of sleep: how rest enhances language learning

Gold Cross | December 10, 2024
,

Wise ways to say “no” and why you should think twice before using them

Gold Cross | December 10, 2024

MS Australia launches major EBV research platform to combat MS

Gold Cross | December 3, 2024
,

Pain, psychological distress common in Australian workers: study

Gold Cross | November 25, 2024

Latest Posts

Pharmacist Only
Blooms The Chemist and Pharmacycle save over 10M medicine packs from landfill
Gold Cross | December 10, 2024
Unlocking the science of sleep: how rest enhances language learning
Gold Cross | December 10, 2024
Wise ways to say “no” and why you should think twice before using them
Gold Cross | December 10, 2024

Featured Posts

How genuine conversations impact high performing teams
Gold Cross | December 10, 2024
Protecting your pharmacy: online reviews and defamation explained
Gold Cross | December 3, 2024
Unlock the potential of your pharmacy lease with Lease Concierge
Gold Cross | November 5, 2024

Tags

Scroll To Top